Integra LifeSciences (NASDAQ:IART) Updates FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.410-2.510 for the period, compared to the consensus estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $24.04 on Wednesday. The stock has a market cap of $1.85 billion, a PE ratio of -265.97, a P/E/G ratio of 0.73 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The business’s 50-day simple moving average is $23.71 and its two-hundred day simple moving average is $21.83. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $44.69.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the previous year, the firm earned $0.89 EPS. The firm’s revenue was up 11.5% compared to the same quarter last year. As a group, analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on IART shares. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $23.00.

Insiders Place Their Bets

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.10% of the stock is currently owned by insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.